Wells Fargo & Company Cuts Incyte (NASDAQ:INCY) Price Target to $101.00

Incyte (NASDAQ:INCY) had its price target cut by Wells Fargo & Company from $107.00 to $101.00 in a research note released on Wednesday,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Incyte in a research report on Thursday, January 22nd. Barclays lifted their price target on shares of Incyte from $115.00 to $116.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Piper Sandler boosted their price objective on shares of Incyte from $102.00 to $110.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Morgan Stanley increased their target price on Incyte from $92.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $135.00 target price on shares of Incyte in a report on Wednesday. Nine analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $103.94.

Incyte Price Performance

INCY stock opened at $101.10 on Wednesday. The stock has a market capitalization of $20.12 billion, a price-to-earnings ratio of 15.77, a price-to-earnings-growth ratio of 0.60 and a beta of 0.82. The company has a quick ratio of 3.13, a current ratio of 3.32 and a debt-to-equity ratio of 0.01. Incyte has a 52-week low of $53.56 and a 52-week high of $112.29. The stock’s fifty day simple moving average is $101.73 and its 200-day simple moving average is $94.07.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). The business had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The business’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.43 earnings per share. Equities research analysts expect that Incyte will post 4.86 EPS for the current year.

Insider Buying and Selling

In other Incyte news, EVP Mohamed Khairie Issa sold 10,856 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total value of $1,184,063.92. Following the transaction, the executive vice president directly owned 66,132 shares of the company’s stock, valued at $7,213,017.24. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Thomas Tray sold 2,774 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $100.00, for a total value of $277,400.00. Following the transaction, the insider owned 22,973 shares in the company, valued at approximately $2,297,300. This represents a 10.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 95,225 shares of company stock valued at $9,519,745 in the last 90 days. 17.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Incyte

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC raised its stake in shares of Incyte by 369.3% during the first quarter. NewEdge Advisors LLC now owns 12,597 shares of the biopharmaceutical company’s stock valued at $763,000 after purchasing an additional 9,913 shares during the period. Jones Financial Companies Lllp grew its holdings in Incyte by 15.1% during the 1st quarter. Jones Financial Companies Lllp now owns 4,944 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 648 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Incyte by 6.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 814,559 shares of the biopharmaceutical company’s stock worth $49,322,000 after buying an additional 48,751 shares during the period. United Services Automobile Association acquired a new position in Incyte in the 1st quarter worth $219,000. Finally, Focus Partners Wealth lifted its holdings in Incyte by 74.1% in the 1st quarter. Focus Partners Wealth now owns 21,024 shares of the biopharmaceutical company’s stock worth $1,273,000 after buying an additional 8,951 shares in the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 results & guidance: Incyte reported Q4 revenue above expectations and outlined 10–13% revenue growth for 2026, citing pipeline expansion and new product launches — a clear near-term growth signal that investors rewarded. Incyte outlines 10–13% revenue growth for 2026
• Positive Sentiment: Analyst tone: Coverage pieces and aggregate analyst commentary remain constructive—Wall Street highlights steady growth and the pipeline, helping underpin sentiment despite the EPS miss. Do Wall Street Analysts Like Incyte Corporation Stock?
• Positive Sentiment: Asset monetization: Incyte sold the Wilmington Bracebridge towers to BPG, a real-estate disposition that should free cash / simplify the corporate footprint — modestly positive for cash flow and capital allocation. Incyte’s big downtown Wilmington move…
• Neutral Sentiment: Market commentary: Several pieces ask whether INCY’s ~43% one‑year run makes it “too late” to buy; these are opinion/valuation discussions that influence positioning but don’t change fundamentals immediately. Is It Too Late To Consider Incyte After Its 43% One Year Rally
• Neutral Sentiment: Media flow: Earnings-call highlights and coverage (transcripts, midday movers) are being digested; they offer color but largely reiterate the same beats/risks. Incyte Q4 Earnings Call Highlights
• Neutral Sentiment: Short-interest data appears inconsistent/erroneous in recent filings (reports show zero shares / NaN changes), so short-interest signals aren’t informative right now.
• Negative Sentiment: Opzelura guidance & Jakafi patent fears: A weaker 2026 revenue forecast for Opzelura raised renewed concerns about franchise vulnerability and potential spillover to Jakafi patent litigation/renewed competitive risk. Opzelura weak 2026 forecast heightens Jakafi patent concerns
• Negative Sentiment: EPS miss & share reaction: INCY missed on EPS for the quarter, which prompted a post‑earnings gap down in some sessions and is a key reason for caution despite the revenue beat. Shares Gap Down After Earnings Miss
• Negative Sentiment: Regulatory/pricing risk: Management flagged exposure to evolving U.S. drug‑pricing policies (e.g., Most Favored Nation‑style measures), which could pressure profitability if enacted. Profit Outlook Threatened by Pricing Policies

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.